Related Experiment Videos
Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study
L E. Schroder1, D Lew, R C. Flanigan
1University of Cincinnati Medical Center, Barrett Cancer Center, P.O. Box 670501, 45219-0501, USA, Cincinnati, OH, USA
Abstract:
Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a maximum toxicity of grade 3. There were no responders; median survival was 10 months. Suramin is not an active agent in advanced renal carcinoma.
Insights
This study found suramin ineffective for advanced renal carcinoma, with no patients responding. While generally tolerated, the drug did not improve median survival, which remained 10 months.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced renal carcinoma presents a significant clinical challenge.
- Investigating novel therapeutic agents is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of suramin in patients with advanced renal carcinoma.
- To determine if suramin demonstrates anti-tumor activity in this patient population.
Main Methods:
- A fixed-dose regimen of suramin was administered to 22 eligible patients.
- Toxicity and patient response were closely monitored throughout the study.
Main Results:
- No objective responses to suramin were observed in any of the patients.
- The median survival for the patient cohort was 10 months.
- Treatment was associated with significant toxicity, with 14% experiencing grade 4 and 50% experiencing grade 3 toxicity.
Conclusions:
- Suramin demonstrated no significant anti-cancer activity in advanced renal carcinoma.
- The observed toxicity profile raises concerns regarding its therapeutic index in this setting.